Key Points
- Carmat has obtained data proving the effectiveness of its artificial heart technology.
- The reimbursement approval (remboursement) process from the French Social Security may begin.
- This approval will change patients' access to the device and the company's commercial roadmap.
French artificial heart specialist Carmat has obtained data proving its technologies work. This development could lead to the company obtaining reimbursement approval from the French Social Security (Assurance Maladie) for its products.
Carmat, a pioneer in artificial heart development, has crossed a commercial and medical threshold by gathering clinical evidence. If reimbursement approval comes, patients' access to these life-saving devices will be significantly eased.
React to this story
Ask about this story
Answers are AI-generated from this story only.
Frequently Asked Questions
- In which field is Carmat a specialized company?
- Carmat is a French medical technology company developing total artificial heart systems.
- What does reimbursement approval (remboursement) mean?
- It means the French health insurance (Assurance Maladie) covers the cost of the device, meaning patients can obtain the device for free or at a very low cost.
- When will this development affect patients?
- The article does not give a specific date; it states the approval process has begun, but the timing of the official decision has not been disclosed.
This is an AI-generated summary. The full story lives at the source.
Read the full story at the sourcebfmtv.comHow we produce our content →Related stories
Health